Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Acquisitions (2016 - 2018)

Historic Acquisitions for Myriad Genetics (MYGN) over the last 4 years, with Q4 2018 value amounting to -$1.1 million.

  • Myriad Genetics' Acquisitions changed N/A to -$1.1 million in Q4 2018 from the same period last year, while for Dec 2020 it was -$1.1 million, marking a year-over-year change of. This contributed to the annual value of $57.2 million for FY2022, which is N/A changed from last year.
  • Per Myriad Genetics' latest filing, its Acquisitions stood at -$1.1 million for Q4 2018.
  • In the past 5 years, Myriad Genetics' Acquisitions registered a high of $279.6 million during Q3 2018, and its lowest value of -$1.1 million during Q4 2018.
  • Its 3-year average for Acquisitions is $98.9 million, with a median of $3.1 million in 2016.